Abstracts tagged "treatment"

Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Kara Bickham¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Nancy Frontera¹, Sandhya Shah¹, Paul Stryszak¹, Dimitris Papanicolaou¹, Zoran Popmihajlov¹ and Paul Peloso¹, ¹Merck & Co., Inc., Kenilworth, NJ, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting
Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Lisa K. Stamp¹, Jill Drake², John L. O'Donnell³, Christopher Frampton⁴ and Peter T. Chapman⁵, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Immunology, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵Rheumatology, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 2428 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database
Helena Canhão¹, Fernando Magalhaes Martins², Jose Antonio Melo Gomes³, Maria Jose Santos⁴, Augusto Faustino⁵, José Antonio Costa⁶, Cornelia Allaart⁷, E. Gvozdenovic⁸, Pedro Machado⁹, Jaime C. Branco¹⁰, João E. Fonseca¹¹ and José Pereira Da-Silva¹², ¹Av. Prof. Egas Moniz, Hospital Santa Maria, Lisboa, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Instituto Português de Reumatologia, Lisbon, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Clínica de Reumatologia de Lisboa, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ⁷Rheumatology, Leiden Univ Med Ctr, Leiden, Netherlands, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹¹Lisbon Academic Medical Center, Lisbon, Portugal, ¹²Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal
Background/Purpose Our aims were to assess disease activity states using DAS28ESR, CDAI and SDAI and to compare their outcomes in two rheumatoid arthritis (RA) populations…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 2395 • 2014 ACR/ARHP Annual Meeting
Understanding Patient Preferences Associated with the Use of Therapies for Rheumatoid Arthritis: Results of a Conjoint Analysis
K. Saverno¹, A. Louder¹, A. Singh², J. Cappelleri³, A. Aten⁴, A. Koenig⁵ and M. Pasquale¹, ¹Comprehensive Health Insights Inc, Louisville, KY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY, ⁴Humana Inc, Louisville, KY, ⁵Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib provides patients with a new oral alternative to biologic…
Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Gerd Burmester¹, Gurjit S. Kaeley², Jeffrey R. Curtis³, Yusuf Yazici⁴, Benoit Guerette⁵, Xin Wang⁵, Alan Friedman⁵ and Vibeke Strand⁶, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²College of Medicine, University of Florida, Jacksonville, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…
Abstract Number: 2406 • 2014 ACR/ARHP Annual Meeting
Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², J. Bourret³ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Injectable biologics are commonly used to treat patients (pts) with moderate to severe rheumatoid arthritis (RA); the frequency with which they are prescribed but…
Abstract Number: 100 • 2014 ACR/ARHP Annual Meeting
Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database
D. Wiederkehr¹, J. Harnett¹, R. Gerber², D. Gruben², E.Y. Mahgoub³, G. Wallenstein¹ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Non-biologic (NB) disease-modifying antirheumatic drugs (DMARD) such as methotrexate (MTX) are commonly used to treat rheumatoid arthritis (RA). However, NB‑DMARD can have adverse events…
Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Francesca Ometto¹, Costantino Botsios², Livio Bernardi¹, Bernd Raffeiner^2,3, Leonardo Punzi⁴ and Andrea Doria⁴, ¹Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, ⁴Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
Abstract Number: 2409 • 2014 ACR/ARHP Annual Meeting
Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis
Ana Carolina Araújo¹, Maria Francisca Moraes-Fontes¹, Lèlita Santos² and Nuno Riso¹, ¹Serviço de Medicina 2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Serviço de Medicina Interna, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints, often with a progressive and destructive course, leading to disability. Nowadays, there…
Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…
Abstract Number: 1529 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
Dick de Vries, Yanli Zhuang, Stanley Marciniak, Zhenhua Xu, Dion Chen, Hugh M. Davis, Honghui Zhou and Francisco Leon, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Interleukin 6 (IL-6) reduces the expression of cytochrome P450 (CYP) enzymes. The goal of the study was to evaluate: 1) the effect of sirukumab…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].